NFA
PVLA

Nationwide Fund Advisors’s Palvella Therapeutics PVLA Stock Holding History

Nationwide Fund Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-241
Closed -$111K – 2190
2017
Q3 		$111K Hold
241
– – ﹤0.01% 2851
2017
Q2 		$98K Buy
+241
New +$70.4K ﹤0.01% 2907

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nationwide Fund Advisors's PVLA Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Palvella Therapeutics (PVLA) in Q4 2017, closing a stake of 241 shares — an estimated $111K sold.

Nationwide Fund Advisors first reported a position in PVLA in Q2 2017 and held it in 2 quarters. The position peaked at $111K in Q3 2017. 90 funds tracked by Wall St. Rank hold PVLA as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Palvella Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 241 Palvella Therapeutics shares in Q4 2017, an estimated $111K.
  • Nationwide Fund Advisors first reported a position in Palvella Therapeutics in Q2 2017 and held it in 2 quarters.
  • Nationwide Fund Advisors's Palvella Therapeutics position peaked at $111K in Q3 2017.
  • 90 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.